Demy-Colton

Jupiter, Florida – October 16, 2026 -- Myosin Therapeutics will present its first-in-class cancer candidate MT-125 at BioFuture 2026 in New York City on October 27–28, seeking investors and pharmaceutical partners to fund an extension into two additional treatment-resistant cancers.

CEO Courtney Miller joins oncology panel on October 27

Chief Executive Officer Courtney Miller, PhD, will speak on the panel "Beyond the Cure: The Brave New World of Revolutionary Cancer Therapeutics." The session covers next-generation cell therapies, AI-enabled cancer drug discovery, precision medicines and advanced therapeutic platforms. Participating CEOs will introduce their companies, followed by a moderated round-robin discussion.

Chief Medical Officer Karen Smith, MD, PhD, MBA, LLM, will join Miller for investor and strategic partner meetings throughout the conference.

New York City – – September 29, 2026 -- Demy-Colton has released the agenda for BioFuture 2026, a two-day conference set for October 27–28 at Cure, 345 Park Avenue South, drawing more than 100 speakers and over 50 presenting companies from biopharma, investment, technology and policy sectors.

Conference agenda spans AI, oncology, biotech financing and global drug development

Speakers include representatives from Johnson & Johnson, Regeneron Pharmaceuticals, Schrödinger, Piper Sandler and Mizuho Securities. Sponsors backing the event include Regeneron Pharmaceuticals, Russo Partners, WuXi AppTec, Blue Matter, Cure, Evotec, Ipsen, Thermo Fisher Scientific, Big4Bio, HMA Consulting, Withum and Hogan Lovells Cadwalader.